Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Study of Nab-Paclitaxel in High Risk Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 2886
- Registration Number
- NCT01690702
- Locations
- 🇩🇪
Klinikum Frankfurt Höchst, Frankfurt, Hessen, Germany
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
- Conditions
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 21
- Registration Number
- NCT01690325
- Locations
- 🇩🇪
Breast Centre, University of Munich, LMU, Munich, Bavaria, Germany
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
- First Posted Date
- 2012-06-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT01630083
- Locations
- 🇷🇺
Site RUS009, Kursk, Russian Federation
🇺🇦Site UKR003, Dnipropetrovsk, Ukraine
🇺🇦Site UKR007, Kyiv, Ukraine
Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-05-08
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 65
- Registration Number
- NCT01594177
- Locations
- 🇩🇪
Rotkreuzklinikum München, München, Germany
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2
- Conditions
- Interventions
- First Posted Date
- 2012-05-07
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT01593020
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
- Conditions
- Interventions
- Drug: DocetaxelDrug: epirubicinProcedure: Modified radical mastectomy or breast-conserving SurgeryDrug: cyclophosphamideDrug: Docetaxel (post-operative)Drug: Epirubicin (post-operative)Drug: Herceptin （post-operative)Drug: Cyclophosphamide (post-operative)Radiation: Radiation therapyDrug: Tamoxifen (post-operative)
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2016-05-24
- Target Recruit Count
- 600
- Registration Number
- NCT01503905
- Locations
- 🇨🇳
Nanfang Hospital of Nanfang Medical University, Guangzhou, Guangdong, China
🇨🇳The first People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳Guangdong Women and Children Hospital, Guangzhou, Guangdong, China
Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2015-09-17
- Lead Sponsor
- Thomas Hatschek
- Target Recruit Count
- 304
- Registration Number
- NCT01433614
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
🇸🇪Kalmar Central Hospital, Kalmar, Sweden
🇸🇪Helsingborg Gen. Hospital, Helsingborg, Sweden
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2012-08-23
- Lead Sponsor
- Zhimin Shao
- Target Recruit Count
- 100
- Registration Number
- NCT01428414
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 12
- Registration Number
- NCT01386346
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4804
- Registration Number
- NCT01358877
- Locations
- 🇺🇸
Texas Oncology - DFW, Dallas, Texas, United States
🇺🇸The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc., Columbus, Ohio, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.